Drugs / Envafolimab
Trials 86 · started per year
today
3
2
2
3
5
24
21
13
9
3
1
201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07260305 | Nov 2024 → Jan 2027 expected | — | Kangabio AUSTRALIA LTD PTY | Recruiting | No outcome recorded |
| Phase 1 | NCT03248843 | Sep 2017 → Mar 2020 | — | 3D Medicines (Sichuan) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03101488 | Mar 2017 → Sep 2019 | cancer | 3D Medicines (Sichuan) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02827968 | Jan 2017 → Aug 2020 | cancer | 3D Medicines (Sichuan) Co., Ltd. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07636798 | Jun 2026 → Mar 2029 expected | biliary tract cancer | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06663007 | Sep 2024 → May 2027 expected | prostate cancer | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06226766 | Jan 2024 → Jul 2025 | neoplasm | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT05448820 | Nov 2022 → Nov 2023 | soft tissue sarcoma | Tracon Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05024214 | Nov 2021 → Dec 2026 expected | hepatocellular carcinoma, non-small cell lung carcinoma, renal cell carcinoma | 3D Medicines (Sichuan) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 272 trials | ||||||
| Phase 2 | NCT04910386 | Jun 2027 → Jun 2029 expected | biliary tract neoplasm | 3D Medicines (Sichuan) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07599995 | May 2026 → Mar 2028 expected | biliary tract cancer | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06059261 | Feb 2026 → Feb 2027 expected | nasopharyngeal carcinoma | Chongqing University Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07283198 | Dec 2025 → Aug 2027 expected | non-small cell lung carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07256223 | Dec 2025 → Nov 2027 expected | clear cell renal carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07159191 | Sep 2025 → Feb 2027 expected | renal cell carcinoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07142863 | Aug 2025 → Aug 2026 overdue | osteosarcoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06772233 | Jul 2025 → Jul 2027 expected | gastrointestinal stromal tumor | Peking University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07559864 | Jul 2025 → Jun 2027 expected | gastrointestinal stromal tumor | Jian Li | Recruiting | No outcome recorded |
| Phase 2 | NCT07003815 | Jun 2025 → Dec 2026 expected | biliary tract cancer | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06692491 | Jan 2025 → Dec 2027 expected | — | Peking University Shenzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06618391 | Oct 2024 → Mar 2026 overdue | non-small cell lung carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06656559 | Oct 2024 → Sep 2025 overdue | biliary tract cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07243626 | Sep 2024 → Dec 2026 expected | soft tissue sarcoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06498622 | Jul 2024 → May 2027 expected | hepatocellular carcinoma | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06734182 | Jun 2024 → Jun 2027 expected | non-small cell lung carcinoma | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06791083 | Jun 2024 → Dec 2025 overdue | gastric cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06321081 | Mar 2024 → Feb 2026 overdue | RASopathy, colorectal cancer | Beijing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06301828 | Feb 2024 → Jun 2025 | digestive system neoplasm | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT06218004 | Jan 2024 → Dec 2025 | — | Hairong Liu | Unknown | No outcome recorded |
| Phase 2 | NCT07266493 | Dec 2023 → Jun 2026 overdue | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05959356 | Nov 2023 → Dec 2026 expected | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06060704 | Nov 2023 → Mar 2025 | colorectal cancer | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT06108726 | Oct 2023 → Jan 2025 | non-small cell lung carcinoma | Northern Jiangsu People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06055816 | Sep 2023 → Sep 2024 overdue | nasopharyngeal carcinoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06041724 | Sep 2023 → Sep 2025 | mucosal melanoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05969847 | Aug 2023 → Dec 2027 expected | rectal cancer | 池畔 | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05904015 | Aug 2023 → Dec 2026 expected | lung neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05914389 | Aug 2023 → Aug 2025 overdue | colonic neoplasm | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06014372 | Jul 2023 → Jul 2024 | colon carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05910034 | Jul 2023 → Dec 2025 | non-small cell lung carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05828381 | Jun 2023 → Jun 2025 | — | Fujian Medical University Union Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05858567 | May 2023 → Dec 2024 | rectal cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05799469 | May 2023 → May 2027 expected | cervical cancer | Chongqing University Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05685550 | Apr 2023 → Dec 2025 overdue | — | Tianjin Medical University Cancer Institute and Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05941325 | Apr 2023 → Dec 2026 | sarcoma | Shanghai 6th People's Hospital | Suspended | No outcome recorded |
| Phase 2 | NCT06239870 | Apr 2023 → Sep 2025 | — | Yunnan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06013943 | Mar 2023 → May 2025 | gallbladder cancer | Eastern Hepatobiliary Surgery Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05722977 | Feb 2023 → Feb 2026 overdue | — | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05534113 | Dec 2022 → Jun 2025 | non-small cell lung carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05582109 | Oct 2022 → Oct 2023 | — | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06030934 | Oct 2022 → Nov 2024 | gastroesophageal junction adenocarcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05552651 | Sep 2022 → Dec 2023 | esophageal squamous cell carcinoma | Tao Jiang | Unknown | No outcome recorded |
| Phase 2 | NCT05529355 | Sep 2022 → Sep 2023 | non-small cell lung carcinoma | Anhui Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05551247 | Sep 2022 → Jun 2023 | colorectal neoplasm | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 2 | NCT05465733 | Aug 2022 → Jun 2025 | non-small cell lung carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 2 | NCT05417230 | Aug 2022 → Aug 2024 | biliary tract cancer | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05422183 | Jun → Dec 2022 | malignant epithelial tumor of ovary | Zhongda Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05129189 | Jun 2022 → Jul 2023 | HIV infectious disease | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
| Phase 2 | NCT05330143 | Jun 2022 → May 2024 | HIV infectious disease | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05397769 | Jun 2022 → Jun 2026 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05414630 | Jun 2022 → Jun 2024 | non-small cell lung carcinoma | Anhui Provincial Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05387681 | May 2022 → Jul 2023 | gastroesophageal junction adenocarcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT05360979 | May 2022 → May 2023 | non-small cell lung carcinoma | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 2 | NCT05385185 | May 2022 → May 2024 | neoplastic meningitis | Hebei Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05335460 | May 2022 → May 2023 | colon carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05216653 | Apr 2022 → Mar 2023 | rectum adenocarcinoma | Sir Run Run Shaw Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05298020 | Apr → Dec 2022 | pancreatic neoplasm | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05213221 | Mar → Sep 2022 | hepatocellular carcinoma | Zhejiang University | Completed | No outcome recorded |
| Phase 2 | NCT05112991 | Mar 2022 → Dec 2026 expected | endometrial cancer | 3D Medicines (Sichuan) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05203276 | Mar 2022 → May 2024 | lung neoplasm | The First People's Hospital of Lianyungang | Unknown | No outcome recorded |
| Phase 2 | NCT05237349 | Mar 2022 → Dec 2024 | gastric adenocarcinoma | Liangjun Zhu M.M. | Unknown | No outcome recorded |
| Phase 2 | NCT05243355 | Dec 2021 → Dec 2023 | non-small cell squamous lung carcinoma | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT05068427 | Nov 2021 → Feb 2023 | non-small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05055167 | Aug 2021 → Dec 2024 | non-small cell lung carcinoma | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 2 | NCT04891198 | Aug 2021 → Aug 2027 expected | cancer | 3D Medicines (Sichuan) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT04480502 | Dec 2020 → Oct 2024 | myxofibrosarcoma, undifferentiated pleomorphic sarcoma | Tracon Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04770207 | Nov 2020 → Nov 2029 expected | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT04465890 | Jul 2020 → Aug 2024 | chronic hepatitis B virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04034823 | Sep 2019 → Jan 2021 | HER2 positive breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04182789 | Mar 2019 → Feb 2021 | — | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03667170 | Aug 2018 → Dec 2026 expected | cancer | 3D Medicines (Sichuan) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06959693 | Jun 2025 → Sep 2028 expected | colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06123754 | Nov 2023 → Dec 2027 expected | non-small cell lung carcinoma | 3D Medicines (Sichuan) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05752136 | Apr 2023 → Apr 2025 overdue | rectal cancer | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT03478488 | Apr 2018 → Sep 2024 overdue | biliary tract neoplasm | 3D Medicines (Sichuan) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07573943 | May 2024 → Dec 2026 expected | chronic hepatitis B virus infection | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06074497 Comparator | Dec 2023 → May 2026 overdue | — | Kangabio AUSTRALIA LTD PTY | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05849311 Comparator | May → Nov 2023 | — | 3D Medicines (Sichuan) Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07327411 Background | Dec 2025 → Feb 2027 expected | refractory malignant neoplasm | Second Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06698965 Background | Oct 2024 → Oct 2029 expected | small cell lung carcinoma | Shanghai Chest Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06702566 Background | Jul 2024 → Jul 2026 overdue | acute leukemia, cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 92 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | envafolimab | “Based on phase I clinical trial data of Envafolimab, a dose reduction design was conducted to minimize the incidence of adverse events while ensuring therapeutic efficacy.” NCT05914389 ↗81“Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.” PMID 35932387 ↗ Aug 2022 “The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.” NCT06123754 ↗ “JSKN033 is a fixed-dose combination consisting of JSKN003 (a HER2-targeted ADC) and envafolimab (a PD-L1 inhibitor)” NCT07283198 ↗ “JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.” NCT06226766 ↗ “intraoperative arterial envafolimab and lenvatinib as first-line therapy for unresectable BTC” NCT07636798 ↗ “Envafolimab, a humanized single-domain anti-PD-L1 antibody fused to an Fc fragment” PMID 34154614 ↗ Jun 2021 “Envafolimab: 150mg, subcutaneous injection, administered on days 1, 8, and 15” NCT07266493 ↗ “PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.” NCT06702566 ↗ “Envafolimab: 400 mg on Day 1, repeated every 3 weeks (Q3W).” NCT07599995 ↗ “PD-L1 inhibitor，Envafolimab 400mg，d1，q3w, until PD” NCT07327411 ↗ “Drug: Envafolimab” NCT06060704 ↗ “Envafolimab” NCT06618391 ↗ |
| Known as | ASC22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04465890 ↗ |
| Known as | Envolimab | “Envafolimab indication: Envolimab is the world's first subcutaneous injection of PD-L1 monoclonal antibody.” NCT05203276 ↗ |
| Known as | KN035 | “Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.” PMID 35932387 ↗ Aug 2022 |
| Known as | KN053 | “Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW). Other Name: KN053” NCT05752136 ↗ |
| Action | Inhibit | “Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors” NCT02827968 ↗ |
| Modality | Monoclonal antibody | “KN035 is a monoclonal antibody drug” NCT02827968 ↗ |
| Route | Subcutaneous | “formulated for subcutaneous injection” NCT02827968 ↗ |
| Target | CD274 | “a PD-L1 inhibitor” NCT07283198 ↗ |